FDA Leaders Draft Guidance On Individualized Gene Therapy Approval Path

FDA senior leaders are preparing draft guidance on an individualized gene therapy approval path as part of their Rare Disease Framework Initiative, aiming to make drug review more predictable and accelerate treatment availability for patients with rare diseases.

This Wire brief sits within Fusion42's coverage of Biotech.